Literature DB >> 23321122

Prognostic significance of quantitative carcinoembryonic antigen and cytokeratin 20 mRNA detection in peritoneal washes of gastric cancer patients.

Sung Ryol Lee, Hyung Ook Kim, Jun Ho Shin, Chang Hak Yoo.   

Abstract

BACKGROUND/AIMS: Peritoneal carcinomatosis is the most common recurrence type in gastric cancer. Disseminated tumor cells derived from serosal invasion may be indicators of early peritoneal seeding and subsequent peritoneal dissemination. Reverse-transcriptase polymerase chain reaction (RT-PCR) techniques have been introduced to aid in detection of disseminated tumor cells in peritoneal washes, however, use of a single molecular marker lacks adequate sensitivity. We sought to improve both sensitivity and specificity in detecting disseminated tumor cells in peritoneal washes by using two markers; carcinoembryonic antigen (CEA) and cytokeratin 20 mRNA (CK20 mRNA).
METHODOLOGY: Between July 2007 and June 2010, peritoneal washing samples were collected from 131 patients who underwent surgery for histologically proven gastric cancer. CEA and CK20 mRNA levels were quantified using a Light Cycler.
RESULTS: Analysis using of the two markers had higher sensitivity (93.9%) and specificity (87.7%) than single marker detection (p<0.01, p<0.001 respectively). These analyses also correlated with various clinicopathological factors, and aided in predicting survival and peritoneal recurrence.
CONCLUSIONS: Two-marker analysis has a significant correlation of survival or peritoneal recurrence in gastric cancer, and this analysis may be more useful as a prognostic predictor of peritoneal recurrence compared with RT-PCR mediated detection of CEA or CK20 alone.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23321122     DOI: 10.5754/hge121058

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

1.  Clinical importance of a transcription reverse-transcription concerted (TRC) diagnosis using peritoneal lavage fluids obtained pre- and post-lymphadenectomy from gastric cancer patients.

Authors:  Keijiro Sugimura; Yoshiyuki Fujiwara; Takeshi Omori; Masaaki Motoori; Norikatsu Miyoshi; Hirofumi Akita; Kunihito Gotoh; Shogo Kobayashi; Hidenori Takahashi; Shingo Noura; Masayuki Ohue; Takashi Yamamoto; Masato Sakon; Masahiko Yano
Journal:  Surg Today       Date:  2015-08-14       Impact factor: 2.549

2.  Downregulation of a long noncoding RNA-ncRuPAR contributes to tumor inhibition in colorectal cancer.

Authors:  Bing Yan; Wei Gu; Zhihui Yang; Zhan Gu; Xiaoqiang Yue; Qunhao Gu; Long Liu
Journal:  Tumour Biol       Date:  2014-08-14

3.  ncRuPAR inhibits gastric cancer progression by down-regulating protease-activated receptor-1.

Authors:  Long Liu; Bing Yan; Zhihui Yang; Xiaodong Zhang; Qunhao Gu; Xiaoqiang Yue
Journal:  Tumour Biol       Date:  2014-05-12

4.  Decreased expression of long noncoding RNA AC096655.1-002 in gastric cancer and its clinical significance.

Authors:  Weiliang Sun; Yibo Wu; Xing Yu; Yang Liu; Haojun Song; Tian Xia; Bingxiu Xiao; Junming Guo
Journal:  Tumour Biol       Date:  2013-05-04

5.  Prognostic value of CEA and CK20 mRNA in the peritoneal lavage fluid of patients undergoing curative surgery for gastric cancer.

Authors:  Akihiro Takata; Yukinori Kurokawa; Yoshiyuki Fujiwara; Yurika Nakamura; Tsuyoshi Takahashi; Makoto Yamasaki; Hiroshi Miyata; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

6.  Prognostic Significance of Molecular Analysis of Peritoneal Fluid for Patients with Gastric Cancer: A Meta-Analysis.

Authors:  Kai Deng; Hong Zhu; Mo Chen; Junchao Wu; Renwei Hu; Chengwei Tang
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

7.  LncRNA DQ786243 contributes to proliferation and metastasis of colorectal cancer both in vitro and in vivo.

Authors:  Longci Sun; Hanbing Xue; Chunhui Jiang; Hong Zhou; Lei Gu; Ye Liu; Chunjie Xu; Qing Xu
Journal:  Biosci Rep       Date:  2016-05-06       Impact factor: 3.840

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.